ArticleInternational journal of molecular sciences2026
Biglycan Reconstitutes a Neonatal ECM Signaling Microenvironment to Drive Stem Cell-Mediated Tendon Regeneration via a Scaffold-Free Cell Sheet Platform.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Unlike newborns, tendon injuries in adults usually lead to fibrotic scarring rather than functional regeneration. This difference is primarily due to the loss of neonatal extracellular matrix (nECM) signaling in adulthood. In this study, we investigated the molecular mechanisms by which a key neonatal ECM proteoglycan, biglycan (Bgn), orchestrates the behavior of tendon stem/progenitor cells (TSPCs) within a scaffold-free 3D cell sheet microenvironment that recapitulates native tendon architecture. Through immunofluorescence screening, we confirmed that Bgn is the predominant proteoglycan in neonatal rat Achilles tendons. Functional validation showed that adding Bgn to cell sheet cultures promoted TSPCs proliferation, maintained stem cell properties, induced tendon differentiation, and encouraged anisotropic alignment-effects similar to those of intact neonatal ECM. Immunodepletion experiments confirmed the causal role of Bgn. Notably, transplanting Bgn-conditioned TSPCs sheets into a rat full-thickness Achilles tendon defect model significantly restored final tensile load, collagen maturation, and gait function. These outcomes were statistically indistinguishable from those of the uninjured contralateral limb. These findings confirm that Bgn-functionalized cell sheet therapy is a viable translational strategy that can effectively recreate a natural 3D regenerative microenvironment. This work sheds light on the mechanisms involved in the determination of stem cell fate by the ECM and establishes Bgn-functionalized cell sheet therapy as a translatable, scaffold-free strategy for overcoming fibrotic repair and restoring functional tendon architecture.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.